Compare TOVX & BX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TOVX | BX |
|---|---|---|
| Founded | 2001 | 1985 |
| Country | United States | United States |
| Employees | 16 | 5285 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.7M | 143.0B |
| IPO Year | 2012 | 2007 |
| Metric | TOVX | BX |
|---|---|---|
| Price | $0.30 | $117.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 17 |
| Target Price | $1.00 | ★ $156.53 |
| AVG Volume (30 Days) | 4.5M | ★ 4.6M |
| Earning Date | 05-13-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 3.96% |
| EPS Growth | ★ 89.07 | 6.91 |
| EPS | N/A | ★ 0.83 |
| Revenue | N/A | ★ $14,450,265,000.00 |
| Revenue This Year | N/A | $12.40 |
| Revenue Next Year | N/A | $23.10 |
| P/E Ratio | ★ N/A | $137.75 |
| Revenue Growth | N/A | ★ 9.22 |
| 52 Week Low | $0.16 | $101.73 |
| 52 Week High | $0.86 | $190.09 |
| Indicator | TOVX | BX |
|---|---|---|
| Relative Strength Index (RSI) | 47.44 | 43.61 |
| Support Level | $0.27 | $104.00 |
| Resistance Level | $0.31 | $134.87 |
| Average True Range (ATR) | 0.02 | 3.51 |
| MACD | -0.01 | -1.09 |
| Stochastic Oscillator | 29.98 | 25.80 |
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.
Blackstone is the world's largest alternative-asset manager with $1.304 trillion in total assets under management, including $937.6 billion in fee-earning assets under management, at the end of March 2026. The company operates with scale in each of its major product lines: private equity (27% of fee-earning AUM and 34% of base management fees), real estate/real assets (30% and 33%), credit and insurance (33% and 26%), and other alternatives (10% and 7%). While the firm primarily serves institutional investors (84% of AUM), it also caters to clients in the high-net-worth channel (16%). Blackstone operates through 25 offices in the Americas (8), Europe and the Middle East (9), and the Asia-Pacific region (8).